Levey AS , et al.. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139:137–147.

• PubMed
Levey AS , . National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139:137–147.)| false
• Search Google Scholar
• Export Citation

Chin MP , et al.. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 2014; 20:953–958.

• PubMed
Chin MP , . Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 2014; 20:953–958.)| false
• Search Google Scholar
• Export Citation

Bakris GL , et al.. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015; 314:884–894.

• PubMed
Bakris GL , . Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015; 314:884–894.)| false
• Search Google Scholar
• Export Citation

Klahr S , et al.. Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877–884.

• PubMed
Klahr S , . Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877–884.)| false
• Search Google Scholar
• Export Citation

Lewis JB . Blood pressure control in chronic kidney disease: Is less really more? J Am Soc Nephrol 2010; 21:1086–1092.

• PubMed
Lewis JB . Blood pressure control in chronic kidney disease: Is less really more? J Am Soc Nephrol 2010; 21:1086–1092.)| false
• Search Google Scholar
• Export Citation

Townsend RR . Blood pressure targets in CKD. Adv Chronic Kidney Dis 2015; 22:96–101.

• PubMed
Townsend RR . Blood pressure targets in CKD. Adv Chronic Kidney Dis 2015; 22:96–101.)| false
• Search Google Scholar
• Export Citation

Kovesdy CP , et al.. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014; 174:1442–1449.

• PubMed
Kovesdy CP , . Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014; 174:1442–1449.)| false
• Search Google Scholar
• Export Citation

Anderson AH , et al.. Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. Ann Intern Med 2015; 162:258–265.

• PubMed
Anderson AH , . Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. Ann Intern Med 2015; 162:258–265.)| false
• Search Google Scholar
• Export Citation

Taler SJ , et al.. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013; 62:201–213.

• PubMed
Taler SJ , . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013; 62:201–213.)| false
• Search Google Scholar
• Export Citation

Verbeke F , et al.. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 2014; 29:490–496.

• PubMed
Verbeke F , . A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 2014; 29:490–496.)| false
• Search Google Scholar
• Export Citation

James PA , et al.. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507–520.

• PubMed
James PA , . 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507–520.)| false
• Search Google Scholar
• Export Citation

Wright JT Jr , et al.. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–2116.

• PubMed
Wright JT Jr , . SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–2116.)| false
• Search Google Scholar
• Export Citation

The Collaborative Study Group, Lewis EJ , et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456–1462.

• PubMed
The Collaborative Study Group, Lewis EJ , . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456–1462.)| false
• Search Google Scholar
• Export Citation

Ruggenenti PI , et al.. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359–364.

• PubMed
Ruggenenti PI , . Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359–364.)| false
• Search Google Scholar
• Export Citation

Brenner BM , et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.

• PubMed
Brenner BM , . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.)| false
• Search Google Scholar
• Export Citation

Jafar TH , et al.. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73–87.

• PubMed
Jafar TH , . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73–87.)| false
• Search Google Scholar
• Export Citation

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997.

• PubMed
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997.)| false
• Search Google Scholar
• Export Citation

Wright JT Jr , et al.. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288:2421–2431.

• PubMed
Wright JT Jr , . African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288:2421–2431.)| false
• Search Google Scholar
• Export Citation

Barnett AH1 , et al.. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952–1961.

• PubMed
Barnett AH1 , . Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952–1961.)| false
• Search Google Scholar
• Export Citation

Mann JF , et al.. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547–553.

• PubMed
Mann JF , . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547–553.)| false
• Search Google Scholar
• Export Citation